Health
Amplia Therapeutics says ‘priming’ a tumour could improve outcomes for patients with pancreatic cancer – Small Caps
New research describing the fundamental biology behind Amplia Therapeutics’ (ASX: ATX) planned phase 2 clinical trial on pancreatic…
New research describing the fundamental biology behind Amplia Therapeutics (ASX: ATX) planned phase 2 clinical trial on pancreatic cancer patients has highlighted the potential benefits of using a focal adhesion kinase (FAK) inhibitor prior to administering…
Continue Reading
-
Business24 hours agoWhy Amotiv, Breville, Life360, and Woodside shares are tumbling today
-
Noosa News23 hours agoDingoes bite 3 women on K’gari
-
Noosa News15 hours agoBrisbane doctor jailed for trafficking ‘breathtaking amount’ of drugs
-
Noosa News23 hours agoNoosa MP calls for solutions to curb reckless electric bike usage